Joost Peerbooms

134 Chapter 8 32. Li F, Li Y, Qiao C, et al. Topical use of platelet-rich plasma can improve the clinical outcomes after total knee arthroplasty: A systematic review and meta-analysis of 1316 patients. Int J Surg. 2017; 38: 109-16. 33. Ma J, Sun J, Guo W, et al. The effect of platelet-rich plasma on reducing blood loss after total knee arthroplasty: A systematic review and meta-analysis. Medicine (Baltimore). 2017; 96(26): e7262. 34. Le A, Enweze L, DeBaun M, et al. Current Clinical Recommendations for Use of Platelet-Rich Plasma. Curr Rev Musculoskelet Med. 2018; 11: 624–34. 35. Mazzucco L, Balbo V, Cattana E, et al. Not every PRP-gel is born equal. Evaluation of growth factor availability for tissues through four PRP-gel preparations: Fibrinet, RegenPRP-Kit, Plateltex and one manual procedure. Vox Sang. 2009; 97(2): 110-18. 36. Amin I, Gellhorn AC. Platelet-Rich Plasma Use in Musculoskeletal Disorders: Are the Factors Important in StandardizationWell Understood? Phys.MedRehabil ClinNAm. 2019; 30: 439–49. 37. Boswell S, Cole B, Sundman E, et al. Platelet- rich plasma: a milieu of bioactive factors. Arthroscopy. 2012; 28: 429–39. 38. Castillo T, PouliotM, KimH, et al. Comparison of growth factor and platelet concentration from commercial platelet-rich plasma separation systems. Am J Sports Med. 2011; 39: 266–71. 39. Mazzocca A, McCarthy M, Chowaniec D, et al. Platelet-rich plasma differs according to preparation method and human variability. J Bone Joint Surg [Am]. 2012; 94: 308–16. 40. Anitua E, Troya M, Zalduendo M, et al. Personalized plasma-based medicine to treat age- related diseases. Mater Sci Eng C Mater Biol Appl. 2017; 74: 459–64. 41. Dhillon R, Schwarz E, Maloney M. Platelet-rich plasma therapy-future or trend? Arthritis Res Ther. 2012; 14: 219. 42. Lansdown D, Fortier L. Platelet-Rich Plasma: Formulations, Preparations, Constituents, and Their Effects. Oper Tech Sports Med. 2017; 25: 7–12. 43. Dhurat R, Sukesh M. Principles and methods of preparation of plate- let-rich plasma: a review and author’s perspective. J Cutan Aesthet Surg. 2014; 7(4): 189-97. 44. Fukaya M, Ito A. A New Economic Method for Preparing Platelet-rich Plasma. Plast Reconstr Surg Glob Open. 2014; 2: e162. 45. Collins T, Alexander D, Barkatali B. Platelet-rich plasma: a narrative review. 2021; 6(4): DOI: 10.1302/2058-5241.6.200017 46. DeLong J, Russell R, Mazzocca A. Platelet-rich plasma: The PAW classification system. Arthroscopy. 2012; 28: 998–1009. 47. Melo B, Luzo A, Lana J, et al. Centrifugation Conditions in the L-PRP Preparation Affect Soluble Factors Release and Mesenchymal Stem Cell Proliferation in Fibrin Nanofibers. Molecules. 2019, 24(15): 2729. 48. Dohan Ehrenfest D, Bielecki T, Jimbo R, et al. Do the fibrin architecture and leukocyte content influence the growth factor release of platelet concentrates? An evidence-based answer comparing a pure platelet-rich plasma (P-PRP) gel and a leukocyte- and platelet-rich fibrin (L-PRF). Curr Pharm Biotechnol. 2012; 13(7): 1145–52. 49. LimW, Park S, Kim B, et al. Relationship of cytokine levels and clinical effect on platelet-rich plasma-treated lateral epicondylitis. J Orthop Res. 2018; 36: 913–20.